Core Viewpoint - The stock price of Prise has shown significant fluctuations, with a year-to-date increase of 74.65% but a recent decline of 1.20% over the last five trading days [2]. Company Overview - Prise (Shanghai) Pharmaceutical Technology Development Co., Ltd. was established on February 22, 2013, and went public on May 17, 2022. The company is located at 500 Guangdong Road, 23rd Floor, World Trade Building, Huangpu District, Shanghai [2]. - The main business involves technology development, transfer, consulting, and services in the pharmaceutical field, with 100% of its revenue coming from services [2]. - The company belongs to the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2]. Financial Performance - For the first half of 2025, Prise reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2]. - Since its A-share listing, Prise has distributed a total of 40.77 million yuan in dividends [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Prise was 8,571, a decrease of 1.88% from the previous period, with an average of 8,787 circulating shares per person, an increase of 1.91% [2]. - The top ten circulating shareholders include Tianhong Medical Health A, which holds 1.4287 million shares, a decrease of 17,600 shares from the previous period, and Rongtong Health Industry Flexible Allocation Mixed A/B, which holds 1 million shares, an increase of 100,000 shares [3].
普蕊斯涨2.42%，成交额3640.20万元，主力资金净流入128.51万元